NeuroSense Therapeutics (NRSN) announced today that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its proprietary treatment drug for amyotrophic lateral sclerosis (ALS) in certain key territories. NeuroSense would retain full rights to PrimeC in other key territories.
The binding term sheet with the leading global pharmaceutical company includes a substantial upfront payment, funding for the Phase 3 study, milestone payments, and double-digit royalties on annual net sales. The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025.